187 related articles for article (PubMed ID: 37873189)
21. NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.
Loskutov YV; Kozyulina PY; Kozyreva VK; Ice RJ; Jones BC; Roston TJ; Smolkin MB; Ivanov AV; Wysolmerski RB; Pugacheva EN
Oncogene; 2015 Jul; 34(28):3662-75. PubMed ID: 25241893
[TBL] [Abstract][Full Text] [Related]
22. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.
Wong CW; Evangelou C; Sefton KN; Leshem R; Zhang W; Gopalan V; Chattrakarn S; Fernandez Carro ML; Uzuner E; Mole H; Wilcock DJ; Smith MP; Sergiou K; Telfer BA; Isaac DT; Liu C; Perl NR; Marie K; Lorigan P; Williams KJ; Rao PE; Nagaraju RT; Niepel M; Hurlstone AFL
Nat Commun; 2023 Sep; 14(1):5983. PubMed ID: 37752135
[TBL] [Abstract][Full Text] [Related]
23. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW; Kuilman T; Ligtenberg MA; Boshuizen J; Stecker KE; de Bruijn B; Krijgsman O; Huang X; Kenski JCN; Lacroix R; Mezzadra R; Gomez-Eerland R; Yildiz M; Dagidir I; Apriamashvili G; Zandhuis N; van der Noort V; Visser NL; Blank CU; Altelaar M; Schumacher TN; Peeper DS
Cell; 2019 Jul; 178(3):585-599.e15. PubMed ID: 31303383
[TBL] [Abstract][Full Text] [Related]
24. Role of ARF6 in internalization of metal-binding proteins, metallothionein and transferrin, and cadmium-metallothionein toxicity in kidney proximal tubule cells.
Wolff NA; Lee WK; Abouhamed M; Thévenod F
Toxicol Appl Pharmacol; 2008 Jul; 230(1):78-85. PubMed ID: 18353411
[TBL] [Abstract][Full Text] [Related]
25. A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade.
Panda A; Betigeri A; Ganesan S
Front Genet; 2022; 13():706468. PubMed ID: 35309122
[TBL] [Abstract][Full Text] [Related]
26. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy.
Du W; Frankel TL; Green M; Zou W
Cell Mol Immunol; 2022 Jan; 19(1):23-32. PubMed ID: 34385592
[TBL] [Abstract][Full Text] [Related]
27. Calcium-regulated exocytosis of dense-core vesicles requires the activation of ADP-ribosylation factor (ARF)6 by ARF nucleotide binding site opener at the plasma membrane.
Vitale N; Chasserot-Golaz S; Bailly Y; Morinaga N; Frohman MA; Bader MF
J Cell Biol; 2002 Oct; 159(1):79-89. PubMed ID: 12379803
[TBL] [Abstract][Full Text] [Related]
28. ARF6 targets recycling vesicles to the plasma membrane: insights from an ultrastructural investigation.
D'Souza-Schorey C; van Donselaar E; Hsu VW; Yang C; Stahl PD; Peters PJ
J Cell Biol; 1998 Feb; 140(3):603-16. PubMed ID: 9456320
[TBL] [Abstract][Full Text] [Related]
29. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
30. Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.
Geng D; Wu H
J Gastrointest Oncol; 2022 Jun; 13(3):958-967. PubMed ID: 35837166
[TBL] [Abstract][Full Text] [Related]
31. Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.
Apriamashvili G; Vredevoogd DW; Krijgsman O; Bleijerveld OB; Ligtenberg MA; de Bruijn B; Boshuizen J; Traets JJH; D'Empaire Altimari D; van Vliet A; Lin CP; Visser NL; Londino JD; Sanchez-Hodge R; Oswalt LE; Altinok S; Schisler JC; Altelaar M; Peeper DS
Nat Commun; 2022 Apr; 13(1):1923. PubMed ID: 35395848
[TBL] [Abstract][Full Text] [Related]
32. PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.
Tao H; Jin C; Zhou L; Deng Z; Li X; Dang W; Fan S; Li B; Ye F; Lu J; Kong X; Liu C; Luo C; Zhang Y
Cancer Res; 2024 Feb; 84(3):419-433. PubMed ID: 37991725
[TBL] [Abstract][Full Text] [Related]
33. Arf6 regulates RhoB subcellular localization to control cancer cell invasion.
Zaoui K; Rajadurai CV; Duhamel S; Park M
J Cell Biol; 2019 Nov; 218(11):3812-3826. PubMed ID: 31591185
[TBL] [Abstract][Full Text] [Related]
34. Internalization of exogenous ADP-ribosylation factor 6 (Arf6) proteins into cells.
Afroze SH; Uddin MN; Cao X; Asea A; Gizachew D
Mol Cell Biochem; 2011 Aug; 354(1-2):291-9. PubMed ID: 21523371
[TBL] [Abstract][Full Text] [Related]
35. ADP-ribosylation factor 6 regulates mu-opioid receptor trafficking and signaling via activation of phospholipase D2.
Rankovic M; Jacob L; Rankovic V; Brandenburg LO; Schröder H; Höllt V; Koch T
Cell Signal; 2009 Dec; 21(12):1784-93. PubMed ID: 19666113
[TBL] [Abstract][Full Text] [Related]
36. ARF6 promotes the formation of Rac1 and WAVE-dependent ventral F-actin rosettes in breast cancer cells in response to epidermal growth factor.
Marchesin V; Montagnac G; Chavrier P
PLoS One; 2015; 10(3):e0121747. PubMed ID: 25799492
[TBL] [Abstract][Full Text] [Related]
37. Exchange factor EFA6R requires C-terminal targeting to the plasma membrane to promote cytoskeletal rearrangement through the activation of ADP-ribosylation factor 6 (ARF6).
Kanamarlapudi V
J Biol Chem; 2014 Nov; 289(48):33378-90. PubMed ID: 25296758
[TBL] [Abstract][Full Text] [Related]
38. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
[TBL] [Abstract][Full Text] [Related]
39. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Benci JL; Johnson LR; Choa R; Xu Y; Qiu J; Zhou Z; Xu B; Ye D; Nathanson KL; June CH; Wherry EJ; Zhang NR; Ishwaran H; Hellmann MD; Wolchok JD; Kambayashi T; Minn AJ
Cell; 2019 Aug; 178(4):933-948.e14. PubMed ID: 31398344
[TBL] [Abstract][Full Text] [Related]
40. ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.
Hashimoto A; Hashimoto S
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
